STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 23 - Issue 4, October-December 2021
SHORT REPORTS
TOCILIZUMAB TREATMENT IN GRAVES ORBITOPATHY
SÁNCHEZ RUIZ ANDRÉS, CLARAMUNT GARCÍA RAQUEL, MUÑOZ CID CARMEN LUCÍA, VILLALOBOS TORRES LORENZO, ZAMORA ARDOY MARÍA AURORA , GÁMEZ PALOMARES ANTONIA


Graves Orbitopathy (GO) is an autoimmune disorder and the most common and major extrathyroid manifestation of Graves’disease. The major ocular symptoms include excessive tearing, eye or retroocular discomfort or pain, blurring of vision, diplopia, or loss of vision. For patients with moderate-to-severe orbitopathy, current evidence indicates initial treatment with glucocorticoids, but in patients whose high-dose glucocorticoid therapy is contraindicated, cannot be tolerated or is ineffective; options include other off-label therapies like intravenous tocilizumab. With current evidence, doubts remain about the duration of treatment. We present a case of a 62-years-old female with corticosteroid-resistant GO. She was treated with a regimen of five doses every four weeks plus two extra doses beginning at week 44. Our patient had a good response to tocilizumab retreatment, with a further improvement after the last doses.

EYE – GRAVES – HYPERTHYROIDISM – ORBITOPATHY – TOCILIZUMAB



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 33,88